Company news
Edgewise Therapeutics, Inc. news in 2022
Edgewise Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
December 20, 2022
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
December 19, 2022
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results
November 2, 2022
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
October 26, 2022
Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
October 12, 2022
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society
October 5, 2022
Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 15, 2022
Edgewise Therapeutics Announces Proposed Offering of Common Stock
September 12, 2022
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
September 12, 2022
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
September 10, 2022
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
September 6, 2022
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
August 3, 2022
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
August 2, 2022
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
July 11, 2022
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
June 19, 2022
New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference
June 15, 2022
Edgewise Therapeutics Reports First Quarter 2022 Financial Results
May 10, 2022
Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling
April 13, 2022
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference
March 7, 2022
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16
February 1, 2022
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
January 4, 2022
Decks in 2022
- 27th International Annual Congress of the World Muscle Society 2022
Conference · 98 slides · Oct 14, 2022
- PPMD Connect Conference 2022
Conference · 15 slides · 2022